{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:31:34Z","timestamp":1763037094366},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ijantimicag.2017.06.024","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T19:45:50Z","timestamp":1499715950000},"page":"227-234","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany"],"prefix":"10.1016","volume":"51","author":[{"given":"Harald","family":"Seifert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"K\u00f6rber-Irrgang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kresken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Swidsinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-M.","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Podbielski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Weise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gl\u00f6ckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kniehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.-A.","family":"Wichelhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0010","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to Gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"year":"2013","series-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","key":"10.1016\/j.ijantimicag.2017.06.024_bib0015"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0020","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.37.30339","article-title":"National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014","volume":"21","author":"Jayol","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0030","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2007.05.019","article-title":"Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa","volume":"30","author":"Takeda","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0040","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0045","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2015.07.004","article-title":"In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study","volume":"46","author":"Tato","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0050","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0055","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","article-title":"Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"author":"International Organization for Standardization","key":"10.1016\/j.ijantimicag.2017.06.024_bib0070"},{"author":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST)","key":"10.1016\/j.ijantimicag.2017.06.024_bib0075"},{"year":"2016","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.ijantimicag.2017.06.024_bib0080"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QCO.0000000000000313","article-title":"Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups: what can be done?","volume":"29","author":"Metan","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.024_bib0090","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2015.10.008","article-title":"Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"85","author":"Martirosov","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.ijantimicag.2017.06.024_bib0095"},{"author":"Kresken","key":"10.1016\/j.ijantimicag.2017.06.024_bib0100"},{"author":"Kresken","key":"10.1016\/j.ijantimicag.2017.06.024_bib0105"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791730273X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791730273X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:31:40Z","timestamp":1668713500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791730273X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S092485791730273X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.024","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}